Search clinical trials for: Lirilumab

Total 69 results

Assistance Publique - Hôpitaux de Paris

Unknown

Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI (CORIMUNO-SARI)

Corona Virus Infection

France
Westyn Branch-Elliman

Completed

Sarilumab for Patients With Moderate COVID-19 Disease

COVID

United States
Clinica Universidad de Navarra, Universidad de...
Sanofi; Hospital Universitario Infanta Leonor

Unknown

Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19 (STRIKESARS)

COVID-19 Drug Treatment

Spain
Amgen

Completed

Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Belgium, Canada, Denmark, Italy, Hungary, Germany, Switzerland, Netherlands, Australia, Russian Federation, Austria, France, United Kingdom, Czechia, Greece, Poland, Estonia, Latvia, Norway
Amgen

Completed

Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease

Crohn's Disease

United States, Canada, Denmark, Belgium, Hungary, Switzerland, Netherlands, Austria, Czechia, France, United Kingdom, Germany
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

An Observational Study on Sarilumab-exposed Pregnancies

Rheumatoid Arthritis -Exposure During Pregnancy

United States, Canada
GlaxoSmithKline
Iqvia Pty Ltd

Completed

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors (contRAst 3)

Arthritis, Rheumatoid

United States, Germany, Canada, Czechia, Poland, South Africa, Korea, Republic of, Spain, Japan, Argentina, Belgium, Hungary, United Kingdom, Italy, Lithuania
ASST Fatebenefratelli Sacco

Recruiting

Study on the Use of Sarilumab in Patients With COVID-19 Infection

COVID19

Italy
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis

Indolent Systemic Mastocytosis

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19

COVID-19

United States
Massachusetts General Hospital
Regeneron Pharmaceuticals

Withdrawn

Study to Assess Sarilumab in Halting Progression of Morphea

Morphea, Plaque Form

United States
Stanford University

Completed

Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis

Sarcoidosis

United States
Bristol-Myers Squibb

Completed

A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

Multiple Myeloma

United States, Spain
University of Southern Denmark
Odense University Hospital; Sygehus Lillebaelt; Odense Patient Data Explorative... and other collaborators

Terminated

Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid Arthritis

Arthritis, Rheumatoid | Interaction

Denmark
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)

Juvenile Idiopathic Arthritis

Argentina, Bulgaria, Canada, Finland, France, Germany, Ireland, Italy, Russian Federation, Spain, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Terminated

Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis (SUSTAIN)

Ankylosing Spondylitis

United States, France, Canada, Poland, Netherlands, Spain, Belgium, Hungary, Lithuania, Austria, Czechia, Australia
Dana-Farber Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN

Squamous Cell Carcinoma of the Head and Neck

United States
Sanofi
Regeneron Pharmaceuticals

Completed

An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) (SKYPP)

Juvenile Idiopathic Arthritis

United States, Argentina, Canada, Chile, Czechia, Finland, France, Germany, Italy, Mexico, Netherlands, Poland, Russian Federation, Spain, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)

Rheumatoid Arthritis

United States, Chile, Czechia, Germany, Hungary, Israel, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine, Korea, Republic of, United Kingdom
Maimónides Biomedical Research Institute of Córdoba
Consejería de Salud y Familias - Junta de Andalucía; Red Andaluza de Ensayos...

Completed

Clinical Trial of Sarilumab in Adults With COVID-19 (SARICOR)

SARS-CoV 2 | SARS

Spain
Sanofi
Regeneron Pharmaceuticals

Completed

Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis (ALIGN)

Ankylosing Spondylitis

Germany, Hungary, Belgium, Czechia, Austria, Canada, Lithuania, Poland, Spain, Turkey, France, Netherlands, United States, Australia
Sanofi
Regeneron Pharmaceuticals

Completed

To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA) (SARIL-RA-ONE)

Rheumatoid Arthritis

United States, Chile, Czechia, Estonia, Hungary, Poland, Russian Federation
University of Southern California
National Cancer Institute (NCI)

Recruiting

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) (EMPOWER)

Cancer | Metastatic | Breast | Triple Negative | Disseminated Tumor Cell

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Japan
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Completed

Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Leukemia | Chronic Lymphocytic Leukemia | Lymphocytic Leukemia

United States
PrECOG, LLC.
Bristol-Myers Squibb

Completed

Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (PrE0807)

Bladder Cancer

United States
Innate Pharma

Completed

Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR) (EFFIKIR)

Acute Myeloid Leukemia

France
Gaylis, Norman B., M.D.

Unknown

Measurement of the Structural Efficacy in Active RA Patients Treated With Sarilumab in Combination With MTX and Naive to Biologics

Rheumatoid Arthritis

United States
Maria del Rosario Garcia de Vicuña Pinedo
Instituto de Investigación Sanitaria Hospital Universitario de la Princesa

Completed

Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID) (SARCOVID)

Covid-19

Spain
M.D. Anderson Cancer Center
Regeneron Pharmaceuticals

Recruiting

A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.

Lung Cancer

United States
Sanofi
Regeneron Pharmaceuticals

Terminated

Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

Giant Cell Arteritis

Argentina, Estonia, France, United States, Australia, Belgium, Canada, Croatia, Denmark, Germany, Hungary, Israel, Italy, Netherlands, Portugal, Russian Federation, Slovenia, Spain, Sweden, Switzerland, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Sarilumab COVID-19

Corona Virus Infection

Italy, Japan, Israel, Argentina, Russian Federation, Germany, Spain, Brazil, Chile, Canada, France
Sanofi
Regeneron Pharmaceuticals

Terminated

Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

Polymyalgia Rheumatica

Argentina, Estonia, France, Japan, United States, Australia, Belgium, Canada, Germany, Hungary, Israel, Italy, Netherlands, Russian Federation, Switzerland, United Kingdom, Spain
Bristol-Myers Squibb

Completed

Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor

CANCER, NOS

United States
Instituto de Investigación Marqués de Valdecilla

Unknown

Effect of Sarilumab on Atherosclerotic Disease Assessed by PET/CET in Patients With RA (SARIPET) (SARIPET)

Rheumatoid Arthritis | Atherosclerosis
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors

Advanced Cancer

Japan
Regeneron Pharmaceuticals
Sanofi

Completed

Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

United States
Regeneron Pharmaceuticals

Recruiting

A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018

Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Primary Peritoneal Cancer

United States, Belgium
Regeneron Pharmaceuticals

Recruiting

Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Recurrent Endometrial Cancer | Recurrent Ovarian Cancer | Recurrent Fallopian Tube Cancer | Recurrent Primary Peritoneal Cancer

United States, Spain, Korea, Republic of, Italy, United Kingdom, Netherlands, Belgium, Australia, France, Israel
Regeneron Pharmaceuticals

Recruiting

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

United States
Marius Henriksen

Terminated

Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure (TOCIVID)

Corona Virus Disease

Denmark
Incyte Corporation

Terminated

A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)

Solid Tumors

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Biphenotypic Leukemia

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients (RA-MOBILITY)

Rheumatoid Arthritis

Germany, Hungary, Belgium, United States, Argentina, Australia, Austria, Belarus, Brazil, Canada, Chile, Czechia, Estonia, Finland, Greece, Korea, Republic of, Lithuania, Malaysia, Mexico, New Zealand, Philippines, Poland, Romania, Russian... and more
Sanofi
Regeneron Pharmaceuticals

Completed

A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)

Rheumatoid Arthritis

Japan
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Terminated

Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)

Leukemia

United States
Assistance Publique - Hôpitaux de Paris

Suspended

Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO (CORIMUNO-VIRO)

SARS-CoV-2 Infection | COVID19

France
Bristol-Myers Squibb

Completed

A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors

CANCER,NOS

France, Canada, United States, Switzerland, Spain, Italy
Sanofi
Regeneron Pharmaceuticals

Completed

Sarilumab Effect on the Pharmacokinetics of Simvastatin

Rheumatoid Arthritis

United States, Korea, Republic of, Moldova, Republic of
Tufts Medical Center

Not yet recruiting

Application of N-of-1 Rheumatoid Arthritis

Arthritis, Rheumatoid

United States

Search clinical trials for: Lirilumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations